Sort by
Items per page

Send to

Choose Destination

Best matches for André F[au]:

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. Hortobagyi GN et al. N Engl J Med. (2016)

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. Turner NC et al. N Engl J Med. (2015)

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. Turner NC et al. N Engl J Med. (2018)

Search results

Items: 1 to 50 of 805


Quicker ADC : Unlocking the Hidden Potential of Product Quantization with SIMD.

Andre F, Kermarrec AM, Le Scouarnec N.

IEEE Trans Pattern Anal Mach Intell. 2019 Nov 11. doi: 10.1109/TPAMI.2019.2952606. [Epub ahead of print]


Improving breast cancer sensitivity to paclitaxel by increasing aneuploidy.

Rodrigues-Ferreira S, Nehlig A, Moindjie H, Monchecourt C, Seiler C, Marangoni E, Chateau-Joubert S, Dujaric ME, Servant N, Asselain B, de Cremoux P, Lacroix-Triki M, Arnedos M, Pierga JY, André F, Nahmias C.

Proc Natl Acad Sci U S A. 2019 Nov 19;116(47):23691-23697. doi: 10.1073/pnas.1910824116. Epub 2019 Nov 4.


Reply to A. Katz.

Henry NL, Andre F, Ismaila N, Somerfield MR, Stearns V.

J Clin Oncol. 2019 Nov 1:JCO1902431. doi: 10.1200/JCO.19.02431. [Epub ahead of print] No abstract available.


A Promiscuous CYP706A3 Reduces Terpene Volatile Emission from Arabidopsis Flowers, Affecting Florivores and the Floral Microbiome.

Boachon B, Burdloff Y, Ruan JX, Rojo R, Junker RR, Vincent B, Nicolè F, Bringel F, Lesot A, Henry L, Bassard JE, Mathieu S, Allouche L, Kaplan I, Dudareva N, Vuilleumier S, Miesch L, André F, Navrot N, Chen XY, Werck D.

Plant Cell. 2019 Oct 18. pii: tpc.00320.2019. doi: 10.1105/tpc.19.00320. [Epub ahead of print]


Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies.

Carene D, Tran-Dien A, Lemonnier J, Dalenc F, Levy C, Pierga JY, Jacot W, Canon JL, Richon C, Lacroix L, Caux C, André F, Michiels S.

Breast Cancer Res Treat. 2019 Oct 16. doi: 10.1007/s10549-019-05462-y. [Epub ahead of print]


Lucitanib for the Treatment of HR+/HER2- Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study.

Hui R, Pearson A, Cortes J, Campbell C, Poirot C, Azim HA Jr, Fumagalli D, Lambertini M, Daly F, Arahmani A, Perez-Garcia J, Aftimos P, Bedard PL, Xuereb L, Scheepers ED, Vicente M, Goulioti T, Loibl S, Loi S, Pierrat MJ, Turner NC, Andre F, Curigliano G.

Clin Cancer Res. 2019 Oct 16. doi: 10.1158/1078-0432.CCR-19-1164. [Epub ahead of print]


Human Hepatocytes and Differentiated Adult-Derived Human Liver Stem/Progenitor Cells Display In Vitro Immunosuppressive Properties Mediated, at Least in Part, through the Nonclassical HLA Class I Molecule HLA-G.

Lombard CA, Sana G, LeMaoult J, Najar M, Ravau J, André F, Bouhtit F, Daouya M, Loustau M, Najimi M, Lagneaux L, Carosella ED, Sokal EM.

J Immunol Res. 2019 Sep 12;2019:8250584. doi: 10.1155/2019/8250584. eCollection 2019.


Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis.

Ferreira AR, Di Meglio A, Pistilli B, Gbenou AS, El-Mouhebb M, Dauchy S, Charles C, Joly F, Everhard S, Lambertini M, Coutant C, Cottu P, Lerebours F, Petit T, Dalenc F, Rouanet P, Arnaud A, Martin A, Berille J, Ganz PA, Partridge AH, Delaloge S, Michiels S, Andre F, Vaz-Luis I.

Ann Oncol. 2019 Oct 8. pii: mdz298. doi: 10.1093/annonc/mdz298. [Epub ahead of print]


Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.

Recondo G, Mezquita L, Facchinetti F, Planchard D, Gazzah A, Bigot L, Rizvi AZ, Frias RL, Thiery JP, Scoazec JY, Sourisseau T, Howarth K, Deas O, Samofalova D, Galissant J, Tesson P, Braye F, Naltet C, Lavaud P, Mahjoubi L, Abou Lovergne A, Vassal G, Bahleda R, Hollebecque A, Nicotra C, Ngo-Camus M, Michiels S, Lacroix L, Richon C, Auger N, De Baere T, Tselikas L, Solary E, Angevin E, Eggermont AM, Andre F, Massard C, Olaussen KA, Soria JC, Besse B, Friboulet L.

Clin Cancer Res. 2019 Oct 4. doi: 10.1158/1078-0432.CCR-19-1104. [Epub ahead of print]


Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy.

Park JH, Jonas SF, Bataillon G, Criscitiello C, Salgado R, Loi S, Viale G, Lee HJ, Dieci MV, Kim SB, Vincent-Salomon A, Curigliano G, André F, Michiels S.

Ann Oncol. 2019 Sep 30. pii: mdz395. doi: 10.1093/annonc/mdz395. [Epub ahead of print]


UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO).

Vaz-Luis I, Cottu P, Mesleard C, Martin AL, Dumas A, Dauchy S, Tredan O, Levy C, Adnet J, Rousseau Tsangaris M, Andre F, Arveux P.

ESMO Open. 2019 Sep 8;4(5):e000562. doi: 10.1136/esmoopen-2019-000562. eCollection 2019.


Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis.

O'Leary B, Hrebien S, Beaney M, Fribbens C, Garcia-Murillas I, Jiang J, Li Y, Huang Bartlett C, André F, Loibl S, Loi S, Cristofanilli M, Turner NC.

Clin Chem. 2019 Nov;65(11):1405-1413. doi: 10.1373/clinchem.2019.305805. Epub 2019 Sep 24.


Prognostic value of novel imaging parameters derived from standard cardiovascular magnetic resonance in high risk patients with systemic light chain amyloidosis.

Arenja N, Andre F, Riffel JH, Siepen FAD, Hegenbart U, Schönland S, Kristen AV, Katus HA, Buss SJ.

J Cardiovasc Magn Reson. 2019 Aug 22;21(1):53. doi: 10.1186/s12968-019-0564-1.


Characterization of cowhage-induced pruritus in inflamed and non-inflamed skin.

André F, Fluhr JW, Hawro T, Church MK, Maurer M, Metz M.

J Eur Acad Dermatol Venereol. 2019 Aug 16. doi: 10.1111/jdv.15871. [Epub ahead of print]


Alpelisib for PIK3CA-Mutated Advanced Breast Cancer. Reply.

André F, Mills D, Taran T.

N Engl J Med. 2019 Aug 15;381(7):687. doi: 10.1056/NEJMc1907856. No abstract available.


Structure-Based Virtual Screening Allows the Identification of Efficient Modulators of E-Cadherin-Mediated Cell-Cell Adhesion.

Dalle Vedove A, Falchi F, Donini S, Dobric A, Germain S, Di Martino GP, Prosdocimi T, Vettraino C, Torretta A, Cavalli A, Rigot V, André F, Parisini E.

Int J Mol Sci. 2019 Jul 11;20(14). pii: E3404. doi: 10.3390/ijms20143404.


Author Correction: Genomic characterization of metastatic breast cancers.

Bertucci F, Ng CKY, Patsouris A, Droin N, Piscuoglio S, Carbuccia N, Soria JC, Dien AT, Adnani Y, Kamal M, Garnier S, Meurice G, Jimenez M, Dogan S, Verret B, Chaffanet M, Bachelot T, Campone M, Lefeuvre C, Bonnefoi H, Dalenc F, Jacquet A, De Filippo MR, Babbar N, Birnbaum D, Filleron T, Le Tourneau C, André F.

Nature. 2019 Aug;572(7767):E7. doi: 10.1038/s41586-019-1380-3.


Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update Summary.

Andre F, Ismaila N, Stearns V.

J Oncol Pract. 2019 Sep;15(9):495-497. doi: 10.1200/JOP.19.00264. Epub 2019 Jul 15. No abstract available.


Risen from the dead: Cardiac stereotactic ablative radiotherapy as last rescue in a patient with refractory ventricular fibrillation storm.

Scholz EP, Seidensaal K, Naumann P, André F, Katus HA, Debus J.

HeartRhythm Case Rep. 2019 Mar 21;5(6):329-332. doi: 10.1016/j.hrcr.2019.03.004. eCollection 2019 Jun. No abstract available.


Detection of Human Microchimerism following Allogeneic Cell Transplantation Using Droplet Digital PCR.

Lombard CA, Fabre A, Ambroise J, Ravau J, André F, Jazouli N, Najimi M, Stéphenne X, Smets F, Vaerman JL, Sokal EM.

Stem Cells Int. 2019 Jun 12;2019:8129797. doi: 10.1155/2019/8129797. eCollection 2019.


ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research.

Marchiò C, Scaltriti M, Ladanyi M, Iafrate AJ, Bibeau F, Dietel M, Hechtman JF, Troiani T, López-Rios F, Douillard JY, Andrè F, Reis-Filho JS.

Ann Oncol. 2019 Sep 1;30(9):1417-1427. doi: 10.1093/annonc/mdz204.


Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx.

Andre F, Ismaila N, Henry NL, Somerfield MR, Bast RC, Barlow W, Collyar DE, Hammond ME, Kuderer NM, Liu MC, Van Poznak C, Wolff AC, Stearns V.

J Clin Oncol. 2019 Aug 1;37(22):1956-1964. doi: 10.1200/JCO.19.00945. Epub 2019 May 31.


Genomic characterization of metastatic breast cancers.

Bertucci F, Ng CKY, Patsouris A, Droin N, Piscuoglio S, Carbuccia N, Soria JC, Dien AT, Adnani Y, Kamal M, Garnier S, Meurice G, Jimenez M, Dogan S, Verret B, Chaffanet M, Bachelot T, Campone M, Lefeuvre C, Bonnefoi H, Dalenc F, Jacquet A, De Filippo MR, Babbar N, Birnbaum D, Filleron T, Le Tourneau C, André F.

Nature. 2019 May;569(7757):560-564. doi: 10.1038/s41586-019-1056-z. Epub 2019 May 22. Erratum in: Nature. 2019 Aug;572(7767):E7.


Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.

André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu YS, Inoue K, Takahashi M, Pápai Z, Longin AS, Mills D, Wilke C, Hirawat S, Juric D; SOLAR-1 Study Group.

N Engl J Med. 2019 May 16;380(20):1929-1940. doi: 10.1056/NEJMoa1813904.


ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.

Luchini C, Bibeau F, Ligtenberg MJL, Singh N, Nottegar A, Bosse T, Miller R, Riaz N, Douillard JY, Andre F, Scarpa A.

Ann Oncol. 2019 May 6. pii: mdz116. doi: 10.1093/annonc/mdz116. [Epub ahead of print]


News from the San Antonio Breast Cancer Symposium 2018.

Pfeiler G, André F, Janni W, Steger G, Untch M.

Breast Care (Basel). 2019 Mar;14(1):60-62. doi: 10.1159/000497371. Epub 2019 Feb 13. No abstract available.


IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer.

Cortés J, André F, Gonçalves A, Kümmel S, Martín M, Schmid P, Schuetz F, Swain SM, Easton V, Pollex E, Deurloo R, Dent R.

Future Oncol. 2019 Jun;15(17):1951-1961. doi: 10.2217/fon-2019-0059. Epub 2019 Apr 12.


A closer look at right ventricular 3D volume quantification by transthoracic echocardiography and cardiac MRI.

Greiner S, André F, Heimisch M, Aurich M, Steen H, Katus HA, Mereles D.

Clin Radiol. 2019 Jun;74(6):490.e7-490.e14. doi: 10.1016/j.crad.2019.03.005. Epub 2019 Apr 4.


T cell Bispecific Antibodies in Node-Positive Breast Cancer: Novel Therapeutic Avenue for MHC class I Loss Variants.

Messaoudene M, Mourikis TP, Michels J, Fu Y, Bonvalet M, Lacroix-Trikki M, Routy B, Fluckiger A, Rusakiewicz S, Roberti MP, Cotteret S, Flament C, Poirier-Colame V, Jacquelot N, Ghiringhelli F, Caignard A, Eggermont AMM, Kroemer G, Marabelle A, Arnedos M, Vicier C, Dogan S, Jaulin F, Sammut SJ, Cope W, Caldas C, Delaloge S, McGranahan N, André F, Zitvogel L.

Ann Oncol. 2019 Mar 29. pii: mdz112. doi: 10.1093/annonc/mdz112. [Epub ahead of print]


Fatigue and physical activity in cancer survivors: A cross-sectional population-based study.

Matias M, Baciarello G, Neji M, Di Meglio A, Michiels S, Partridge AH, Bendiane MK, Fizazi K, Ducreux M, Andre F, Vaz-Luis I.

Cancer Med. 2019 May;8(5):2535-2544. doi: 10.1002/cam4.2060. Epub 2019 Mar 12.


Four Major Channels Detected in the Cytochrome P450 3A4: A Step toward Understanding Its Multispecificity.

Benkaidali L, André F, Moroy G, Tangour B, Maurel F, Petitjean M.

Int J Mol Sci. 2019 Feb 25;20(4). pii: E987. doi: 10.3390/ijms20040987.


Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.

Turner NC, Liu Y, Zhu Z, Loi S, Colleoni M, Loibl S, DeMichele A, Harbeck N, André F, Bayar MA, Michiels S, Zhang Z, Giorgetti C, Arnedos M, Huang Bartlett C, Cristofanilli M.

J Clin Oncol. 2019 May 10;37(14):1169-1178. doi: 10.1200/JCO.18.00925. Epub 2019 Feb 26. Erratum in: J Clin Oncol. 2019 Nov 1;37(31):2956.


Beneficial effects of Saccharomyces boulardii CNCM I-745 on clinical disorders associated with intestinal barrier disruption.

Terciolo C, Dapoigny M, Andre F.

Clin Exp Gastroenterol. 2019 Feb 11;12:67-82. doi: 10.2147/CEG.S181590. eCollection 2019. Review.


Census of Octocorallia (Cnidaria: Anthozoa) of the Azores (NE Atlantic) with a nomenclature update.

Íris S, Andre F, Mora PF, Gui M, Marina CS.

Zootaxa. 2019 Jan 29;4550(4):451-498. doi: 10.11646/zootaxa.4550.4.1.


Correction: ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors.

Guerrero-Zotano AL, Stricker TP, Formisano L, Hutchinson KE, Stover DG, Lee KM, Schwarz LJ, Giltnane JM, Estrada MV, Jansen VM, Servetto A, Gavilá J, Perez-Fidalgo JA, Lluch A, Llombart-Cussac A, Bayar MA, Michiels S, André F, Arnedos M, Guillem V, Ruiz-Simon A, Arteaga CL.

Clin Cancer Res. 2019 Feb 15;25(4):1431. doi: 10.1158/1078-0432.CCR-18-4270. No abstract available.


Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.

Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, Campone M, Biganzoli L, Bonnefoi H, Jerusalem G, Bartsch R, Rabaglio-Poretti M, Kammler R, Maibach R, Smyth MJ, Di Leo A, Colleoni M, Viale G, Regan MM, André F; International Breast Cancer Study Group and the Breast International Group.

Lancet Oncol. 2019 Mar;20(3):371-382. doi: 10.1016/S1470-2045(18)30812-X. Epub 2019 Feb 11.


Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).

Condorelli R, Mosele F, Verret B, Bachelot T, Bedard PL, Cortes J, Hyman DM, Juric D, Krop I, Bieche I, Saura C, Sotiriou C, Cardoso F, Loibl S, Andre F, Turner NC.

Ann Oncol. 2019 Mar 1;30(3):365-373. doi: 10.1093/annonc/mdz036.


A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer.

Campone M, Bachelot T, Penault-Llorca F, Pallis A, Agrapart V, Pierrat MJ, Poirot C, Dubois F, Xuereb L, Bossard CJ, Guigal-Stephan N, Lockhart B, Andre F.

Cancer Chemother Pharmacol. 2019 Apr;83(4):743-753. doi: 10.1007/s00280-018-03765-3. Epub 2019 Jan 25.


American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange: From Inception to First Data Release and Beyond-Lessons Learned and Member Institutions' Perspectives.

Micheel CM, Sweeney SM, LeNoue-Newton ML, André F, Bedard PL, Guinney J, Meijer GA, Rollins BJ, Sawyers CL, Schultz N, Shaw KRM, Velculescu VE, Levy MA; AACR Project GENIE Consortium.

JCO Clin Cancer Inform. 2018 Dec;2:1-14. doi: 10.1200/CCI.17.00083. Review.


Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.

Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Lemonnier J, Sotiriou C, Piccart MJ, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, Andre F, Denkert C, Salgado R, Michiels S.

J Clin Oncol. 2019 Mar 1;37(7):559-569. doi: 10.1200/JCO.18.01010. Epub 2019 Jan 16.


Value of adenosine stress cardiovascular magnetic resonance in the evaluation of vessels supplying previously infarcted territories.

Greulich S, Backes M, Steubing H, Seitz A, Chatzitofi M, Kaesemann P, Andre F, Buss SJ, Katus HA, Mahrholdt H.

Coron Artery Dis. 2019 May;30(3):222-231. doi: 10.1097/MCA.0000000000000705.


Dendritic cell-based vaccination: powerful resources of immature dendritic cells against pancreatic adenocarcinoma.

Collignon A, Silvy F, Robert S, Trad M, Germain S, Nigri J, André F, Rigot V, Tomasini R, Bonnotte B, Lombardo D, Mas E, Beraud E.

Oncoimmunology. 2018 Sep 25;7(12):e1504727. doi: 10.1080/2162402X.2018.1504727. eCollection 2018.


Case report of dependent venous contrast pooling and layering in a patient without acute cardiogenic shock.

Wagner WL, Spira D, André F, Kantharajah A, Kauczor HU, Mokry T.

Medicine (Baltimore). 2018 Nov;97(47):e13277. doi: 10.1097/MD.0000000000013277.


Combinatorial expression of microtubule-associated EB1 and ATIP3 biomarkers improves breast cancer prognosis.

Rodrigues-Ferreira S, Nehlig A, Monchecourt C, Nasr S, Fuhrmann L, Lacroix-Triki M, Garberis I, Scott V, Delaloge S, Pistilli B, Vielh P, Dubois T, Vincent-Salomon A, André F, Nahmias C.

Breast Cancer Res Treat. 2019 Feb;173(3):573-583. doi: 10.1007/s10549-018-5026-1. Epub 2018 Oct 27.


Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.

Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, André F, Puyana Theall K, Huang X, Giorgetti C, Huang Bartlett C, Cristofanilli M.

N Engl J Med. 2018 Nov 15;379(20):1926-1936. doi: 10.1056/NEJMoa1810527. Epub 2018 Oct 20.


ABCB1 (P-glycoprotein) regulates vitamin D absorption and contributes to its transintestinal efflux.

Margier M, Collet X, le May C, Desmarchelier C, André F, Lebrun C, Defoort C, Bluteau A, Borel P, Lespine A, Reboul E.

FASEB J. 2019 Feb;33(2):2084-2094. doi: 10.1096/fj.201800956R. Epub 2018 Sep 17.


The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial.

O'Leary B, Cutts RJ, Liu Y, Hrebien S, Huang X, Fenwick K, André F, Loibl S, Loi S, Garcia-Murillas I, Cristofanilli M, Huang Bartlett C, Turner NC.

Cancer Discov. 2018 Nov;8(11):1390-1403. doi: 10.1158/2159-8290.CD-18-0264. Epub 2018 Sep 11.


Cardiovascular magnetic resonance of cardiac morphology and function: impact of different strategies of contour drawing and indexing.

Riffel JH, Schmucker K, Andre F, Ochs M, Hirschberg K, Schaub E, Fritz T, Mueller-Hennessen M, Giannitsis E, Katus HA, Friedrich MG.

Clin Res Cardiol. 2019 Apr;108(4):411-429. doi: 10.1007/s00392-018-1371-7. Epub 2018 Sep 10.


A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).

Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, Ng CKY, Bedard PL, Tortora G, Douillard JY, Van Allen EM, Schultz N, Swanton C, André F, Pusztai L.

Ann Oncol. 2018 Sep 1;29(9):1895-1902. doi: 10.1093/annonc/mdy263.


Added Value of Whole-Exome and Transcriptome Sequencing for Clinical Molecular Screenings of Advanced Cancer Patients With Solid Tumors.

Koeppel F, Bobard A, Lefebvre C, Pedrero M, Deloger M, Boursin Y, Richon C, Chen-Min-Tao R, Robert G, Meurice G, Rouleau E, Michiels S, Massard C, Scoazec JY, Solary E, Soria JC, André F, Lacroix L.

Cancer J. 2018 Jul/Aug;24(4):153-162. doi: 10.1097/PPO.0000000000000322. Review.


Supplemental Content

Support Center